However, GDF9 immunoreactivity (PCOS, 27.73±8.43) was significantly reduced (p<0.05) compared to the other groups (control, 33.72±11.22; vehicle, 33.95±10.75; Table 1, Figure 3a). This evidence concerns the gene GDF9 and polycystic ovary syndrome.